Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41.

Article  CAS  PubMed  Google Scholar 

Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):2247–59.

Article  PubMed  Google Scholar 

Luo Z, Li X, Zhu M, et al. Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy. J Thromb Haemost. 2017;15(1):28–37.

Article  CAS  PubMed  Google Scholar 

Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4051–100.

Article  CAS  PubMed  Google Scholar 

Shukla A, Jain A, Kahalekar V, et al. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin. Hep Intl. 2019;13(2):214–21.

Article  Google Scholar 

Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.

Article  CAS  PubMed  Google Scholar 

Lea JC, Floroff CK, Ingemi AI, et al. Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods. J Thromb Thrombolysis. 2019;47(3):361–8.

Article  CAS  PubMed  Google Scholar 

Carmo J, Ferreira J, Costa F, et al. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials. Int J Cardiol. 2017;244:196–201.

Article  PubMed  Google Scholar 

Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.

Article  CAS  PubMed  Google Scholar 

Rojo M, Roco AM, Suarez M, et al. Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. Clin Appl Thromb Hemost. 2020;26:1076029620909154.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Belley-Cote EP, Hanif H, D’Aragon F, et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemostasis. 2015;114(4):768–77.

Article  Google Scholar 

Sridharan K, Sivaramakrishnan G. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional. J Clin Pharm Ther. 2021;46(3):640–8.

Article  CAS  PubMed  Google Scholar 

Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067.

Article  PubMed  PubMed Central  Google Scholar 

Bernaitis N, Ching CK, Teo SC, et al. Factors influencing warfarin control in Australia and Singapore. Thromb Res. 2017;157:120–5.

Article  CAS  PubMed  Google Scholar 

Henderson JB, Iyer P, Coniglio AC, et al. Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. Pharmacotherapy. 2019;39(10):1030–5.

Article  CAS  PubMed  Google Scholar 

Costa GL, Lamego RM, Colosimo EA, et al. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther. 2012;34(7):1511–20.

Article  CAS  PubMed  Google Scholar 

Eriksson N, Wallentin L, Berglund L, et al. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016;17(13):1425–39.

Article  CAS  PubMed  Google Scholar 

Praxedes MFS, Martins MAP, Mourão AOM, et al. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. Eur J Clin Pharmacol. 2020;76(2):199–209.

Article  CAS  PubMed  Google Scholar 

da Silveira M, Melo LA, Gomes FMF, et al. Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. Appl Clin Genet. 2019;12:151–9.

Article  PubMed  PubMed Central  Google Scholar 

Perreault S, Shahabi P, Côté R, et al. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol. 2018;41(5):576–85.

Article  PubMed  PubMed Central  Google Scholar 

Wypasek E, Mazur P, Bochenek M, et al. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up. J Physiol Pharmacol. 2016;67(3):385–93.

CAS  PubMed  Google Scholar 

Li D, Luo ZY, Chen Y, et al. LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes. J Cardiovasc Pharmacol. 2020;76(1):71–6.

Article  CAS  PubMed  Google Scholar 

Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113(4):784–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa Viana C, da Silva Praxedes MF, Freitas Nunes de Sousa WJ, et al. Sex-influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: Systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(12):4488–503.

Article  CAS  PubMed  Google Scholar 

Marcatto LR, Sacilotto L, Darrieux FC, et al. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. Oncotarget. 2016;7(34):54194–9.

Article  PubMed  PubMed Central  Google Scholar 

Anand A, Kumar R, Gupta A, et al. Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting. Indian Heart J. 2022;74(3):245-8.

Zhou Y, Ma J, Zhu W. Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2020;20(1):51–60.

Article  PubMed  Google Scholar 

Almas T, Muhammad F, Siddiqui L, et al. Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis. Ann Med Surg. 2012;2022(77):103610.

Google Scholar 

Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: Metabolism and perspective in obesity. Gut microbes. 2018;9(4):308–25.

CAS  PubMed  PubMed Central  Google Scholar 

Jorgensen AL, FitzGerald RJ, Oyee J, et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e44064.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeuchi M, Kobayashi T, Biss T, et al. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharmacogenomics J. 2020;20(2):306–19.

Article  CAS  PubMed  Google Scholar 

Yang L, Ge W, Yu F, et al. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement–a systematic review and meta analysis. Thromb Res. 2010;125(4):e159-166.

Article  CAS  PubMed  Google Scholar 

Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893–900.

Article  PubMed  Google Scholar 

Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–96.

Article  CAS  PubMed  Google Scholar 

Lindh JD, Holm L, Andersson ML, et al. Influence of CYP2C9 genotype on warfarin dose requirements–a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009;65(4):365–75.

Article  CAS  PubMed  Google Scholar